Guard Therapeutics International AB (publ) (GUARD.ST)
SEK 12.25
(2.94%)
SEK 12.25
(2.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -114.9 Million SEK | -1.83% |
| 2022 | -112.82 Million SEK | -37.56% |
| 2021 | -82.01 Million SEK | -104.48% |
| 2020 | -40.12 Million SEK | -0.54% |
| 2019 | -43.29 Million SEK | 37.2% |
| 2018 | -64.18 Million SEK | 3.04% |
| 2017 | -65.25 Million SEK | -24.98% |
| 2016 | -52.43 Million SEK | -66.04% |
| 2015 | -29.25 Million SEK | -445.29% |
| 2014 | -13.52 Million SEK | -31.91% |
| 2013 | -4.39 Million SEK | -111.46% |
| 2012 | -2.07 Million SEK | -121.71% |
| 2011 | -936.33 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -17.27 Million SEK | 12.89% |
| 2024 Q2 | -23.68 Million SEK | -63.58% |
| 2023 Q4 | -17.09 Million SEK | 26.76% |
| 2023 Q2 | -32.96 Million SEK | 17.43% |
| 2023 FY | - SEK | -1.83% |
| 2023 Q3 | -23.34 Million SEK | 29.19% |
| 2023 Q1 | -39.91 Million SEK | 1.42% |
| 2022 Q4 | -40.49 Million SEK | -25.09% |
| 2022 Q3 | -32.36 Million SEK | -54.15% |
| 2022 Q2 | -20.99 Million SEK | -10.64% |
| 2022 Q1 | -18.97 Million SEK | 16.44% |
| 2022 FY | - SEK | -37.56% |
| 2021 Q3 | -34.46 Million SEK | -197.55% |
| 2021 FY | - SEK | -104.48% |
| 2021 Q1 | -13.26 Million SEK | -34.7% |
| 2021 Q2 | -11.58 Million SEK | 12.71% |
| 2021 Q4 | -22.71 Million SEK | 34.09% |
| 2020 Q1 | -9.16 Million SEK | -8.2% |
| 2020 Q3 | -12.78 Million SEK | -55.2% |
| 2020 Q4 | -9.85 Million SEK | 22.96% |
| 2020 FY | - SEK | -0.54% |
| 2020 Q2 | -8.23 Million SEK | 10.12% |
| 2019 FY | - SEK | 37.2% |
| 2019 Q3 | -7.79 Million SEK | 27.76% |
| 2019 Q4 | -8.47 Million SEK | -8.7% |
| 2019 Q1 | -12.84 Million SEK | 37.69% |
| 2019 Q2 | -10.78 Million SEK | 16.04% |
| 2018 Q1 | -13.58 Million SEK | 6.21% |
| 2018 Q4 | -20.61 Million SEK | -32.09% |
| 2018 Q3 | -15.6 Million SEK | -13.69% |
| 2018 FY | - SEK | 3.04% |
| 2018 Q2 | -13.72 Million SEK | -1.1% |
| 2017 Q3 | -17.6 Million SEK | 3.08% |
| 2017 Q1 | -15.58 Million SEK | 27.4% |
| 2017 Q4 | -14.47 Million SEK | 17.76% |
| 2017 FY | - SEK | -24.98% |
| 2017 Q2 | -18.16 Million SEK | -16.58% |
| 2016 FY | - SEK | -66.04% |
| 2016 Q3 | -13.3 Million SEK | -18.86% |
| 2016 Q4 | -21.46 Million SEK | -61.34% |
| 2016 Q2 | -11.19 Million SEK | -72.85% |
| 2016 Q1 | -6.47 Million SEK | 46.42% |
| 2015 Q2 | -8.29 Million SEK | -185.87% |
| 2015 Q3 | -6.49 Million SEK | 21.67% |
| 2015 Q1 | -2.9 Million SEK | -102.94% |
| 2015 Q4 | -12.08 Million SEK | -85.98% |
| 2015 FY | - SEK | -445.29% |
| 2014 FY | - SEK | -31.91% |
| 2014 Q4 | -1.43 Million SEK | 15.13% |
| 2014 Q3 | -1.68 Million SEK | -5.78% |
| 2014 Q2 | -1.59 Million SEK | -47.23% |
| 2014 Q1 | -1.08 Million SEK | -31.95% |
| 2013 Q4 | -820 Thousand SEK | 26.06% |
| 2013 FY | - SEK | -111.46% |
| 2013 Q2 | -1.53 Million SEK | -65.09% |
| 2013 Q1 | -928 Thousand SEK | -558.16% |
| 2013 Q3 | -1.1 Million SEK | 27.61% |
| 2012 Q4 | -141 Thousand SEK | 74.41% |
| 2012 Q3 | -551 Thousand SEK | 34.72% |
| 2012 FY | - SEK | -121.71% |
| 2012 Q2 | -844 Thousand SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 68.759% |
| AcouSort AB (publ) | -16.7 Million SEK | -587.942% |
| Active Biotech AB (publ) | -43.88 Million SEK | -161.825% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 273694.609% |
| Amniotics AB (publ) | -27.14 Million SEK | -323.339% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -708.237% |
| BioArctic AB (publ) | 275.38 Million SEK | 141.726% |
| Camurus AB (publ) | 562.54 Million SEK | 120.426% |
| Cantargia AB (publ) | -284.31 Million SEK | 59.585% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -486.889% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -572.58% |
| Genovis AB (publ.) | 64.57 Million SEK | 277.952% |
| Mendus AB (publ) | -97.84 Million SEK | -17.437% |
| Kancera AB (publ) | -61.88 Million SEK | -85.666% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -329.03% |
| LIDDS AB (publ) | -39.67 Million SEK | -189.657% |
| Lipum AB (publ) | -37.11 Million SEK | -209.564% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -849.331% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 465.899% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 5745450.0% |
| NextCell Pharma AB | -40.98 Million SEK | -180.363% |
| OncoZenge AB (publ) | 7.26 Million SEK | 1681.434% |
| Saniona AB (publ) | -69.69 Million SEK | -64.871% |
| Simris Alg AB (publ) | -22.36 Million SEK | -413.826% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 63.805% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 59.258% |
| Xintela AB (publ) | -53.47 Million SEK | -114.896% |
| Ziccum AB (publ) | -20.34 Million SEK | -464.876% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -210.358% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 32.334% |
| CombiGene AB (publ) | -35.33 Million SEK | -225.183% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 18.419% |
| Intervacc AB (publ) | -68.98 Million SEK | -66.58% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 51.641% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -5424.375% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -755.536% |
| Corline Biomedical AB | -1.69 Million SEK | -6695.21% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 33.704% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -109.661% |
| Aptahem AB (publ) | -10 Million SEK | -1048.011% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 1094.952% |
| Fluicell AB (publ) | -25.91 Million SEK | -343.417% |
| Biovica International AB (publ) | -119.5 Million SEK | 3.848% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -172.137% |
| Abliva AB (publ) | -93.6 Million SEK | -22.753% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 63.99% |
| 2cureX AB (publ) | -35.13 Million SEK | -227.035% |
| I-Tech AB | 30.34 Million SEK | 478.669% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 83.919% |
| Cyxone AB (publ) | -20.41 Million SEK | -462.883% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -12.156% |
| Biosergen AB | 228 Thousand SEK | 50497.807% |
| Nanologica AB (publ) | -62.11 Million SEK | -84.979% |
| SynAct Pharma AB | -222.7 Million SEK | 48.403% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -161.98% |
| BioInvent International AB (publ) | -312.7 Million SEK | 63.254% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 37237.095% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 50.39% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -1203.912% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -5.848% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -901.892% |